0.34Open0.34Pre Close0 Volume4 Open Interest9.00Strike Price0.00Turnover811.58%IV134.67%PremiumApr 11, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.34Extrinsic Value100Contract SizeAmericanOptions Type0.2564Delta0.1037Gamma11.71Leverage Ratio-0.1471Theta0.0001Rho3.00Eff Leverage0.0012Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet